MANKIND - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.8
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established around 2,280 ₹ (support level) and 2,350 ₹ (resistance). An exit strategy would involve a stop-loss order at 2,265 ₹ to mitigate potential downside risk if the price breaks below support. Overall, the stock shows mixed signals: momentum is present but accompanied by valuation concerns – a cautious approach with disciplined money management is advised, awaiting further confirmation of directional intent.
✅ Positive
The price is currently trading within a defined channel, suggesting a period of consolidation. Furthermore, the recent increase in DII holding indicates potential buying pressure that may be driving the price upwards. Volume is consistently above its weekly average, reinforcing the momentum.
⚠️ Limitation
Despite the bullish short-term indicators, the high stock P/E ratio (42.1) compared to the industry (34.8) raises concerns about overvaluation, particularly given the recent profit decline and the PEG ratio of 2.07. The downward trend in FII holding also indicates a lack of investor confidence that could trigger a reversal.
📉 Company Negative News
Recent news from Business Standard highlights Mankind Pharma’s share price dropping for five consecutive sessions following an earnings preview, which is a negative signal regarding future profitability expectations.
🏭 Industry
The pharmaceutical sector generally exhibits high PE ratios due to innovation and brand value; however, the current market volatility and concerns about raw material costs are putting pressure on margins across the board within the industry – impacting investor sentiment.